e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:04/April-2024 Impact Factor- 7.868 www.irjmets.com

ADVANCEMENTS IN CANCER IMMUNOTHERAPY: UNRAVELING THE PROMISE OF MRNA VACCINES

Abhishek S. Jaware[*1], Naval D. Chaudhari[*2], Tushar D. Gudade[*3], Pranjal P. Mhaske[*4], Satish S. Palkar[*5], Tanvi V. Bhave[*6], Vikin P. Nagrik[*7], Rutuja R. Hajare[*8]

[*1,2,3,5,7]Student, B.Pharm Final Year, GCP, Sakharkherda, Maharashtra, India.

[*6]Student, B.Pharm Third Year, GCP, Sakharkherda, Maharashtra, India.

[*4]Student, Department of Pharmaceutics M. Pharm, RSCP, Buldhana, Maharashtra, India.

[*8]Student, Bpharm Third Year, YIOP, Chha. Sambhaji Nagar, Maharashtra, India.

ABSTRACT

Cancer immunotherapy has witnessed remarkable progress in recent years, particularly with the advent of FDA-approved checkpoint blockade modulators and CAR-T cell therapies. However, the potential of cancer vaccines, particularly mRNA vaccines, remains underexplored. This review paper delves into the landscape of cancer immunotherapy, focusing on the transformative role of mRNA vaccines in targeting tumor-associated antigens. From enhancing mRNA translation stability to navigating regulatory challenges, this paper navigates through the intricate terrain of mRNA-based cancer immunotherapy, shedding light on its promises and challenges.

Keywords: Cancer Immunotherapy, Mrna Vaccines, Checkpoint Blockade Modulators, CAR-T Cell Therapy, Tumor-Associated Antigens, Regulatory Challenges, Translational Advancements.

I. INTRODUCTION

In recent years, cancer immunotherapies have gained acceptance and shown substantial advancements. FDA approved checkpoint blockade modulators (pembrolizumab and nivolumab in 2014 and 2015, respectively) and CAR-T cell immunotherapies (tisagenle cleucel and axicabtagene ciloleucel in 2017 and 2018) [1]. These immunotherapies enhance the immune system's ability to recognize and eliminate cancer cells. Providing a promising alternative to standard cancer treatments. The approval of these medications highlights cancer immunotherapy as a promising and successful treatment option [2]. Cancer immunotherapies aim to boost the immune system and alter the tumor's microenvironment. These medicines seek to reduce tumor growth and increase patient survival [3]. Cancer immunotherapies can produce long-term remission by stimulating the immune system, making them a viable therapy choice for cancer patients.

Additionally, cancer treatment could have fewer Alternative cancer treatments have fewer adverse effects and can improve patients' quality of life [4].Cancer vaccines offer a possible alternative to immunotherapy for cancer prevention and treatment. Unlike Cancer vaccines, unlike typical vaccines for infectious diseases, target cancer cells by stimulating the immune system. Cancer vaccines can be used as a prophylactic approach in high-risk patients or as a treatment for existing cancers. Cancer vaccines have the potential to transform cancer treatment by providing a focused and tailored approach with fewer adverse effects. compared to standard cancer treatments. Cancer vaccinations show promise as a strategy for prevention and treatment [5].Vaccines targeting tumor-associated or tumor-specific antigens (TAAs or TSAs) have showed promise in targeting and eliminating cancer. Overexpressing certain antigens in cer cells can result in a long-lasting therapeutic response. Cancer cells express TAAs and TSAs, which are distinct from normal cells, making them a promising target for cancer immunotherapy. Vaccinating humans with cancer-specific antigens trains the immune system to recognize and destroy cancer cells. This focused method can elicit a long-lasting immune response, making it an effective treatment choice for cancer patients. Vaccines against TAAs or TSAs have potential for cancer immunotherapy due to their ability to target cancer cells that overexpress certain antigens [6]. Immunologic memory, a feature of the immune system, is vital for the success of cancer vaccinations. This memory enables the immune system.

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:04/April-2024 Impact Factor- 7.868 www.irjmets.com

The ability to recognize and kill cancer cells following initial vaccination exposure. Cancer vaccines provide a targeted, non-toxic, and well-tolerated treatment alternative that differs from previous immunotherapies. Cancer vaccines can stimulate a tailored immune response to cancer-specific antigens, minimizing the risk of unwanted effects and toxicities associated with traditional cancer treatments. Despite extensive research, clinical translation of cancer vaccines into useful treatments remains problematic. decades. One of the main reasons behind the challenge the very diverse nature of tumor antigens makes it challenging to find precise targets for cancer vaccines. Furthermore, the immunological response triggered by cancer vaccinations have often failed to provide a therapeutic impact [7].These issues have slowed the development of effective cancer vaccines, limiting their potential impact on cancer treatment. Research and improvements in cancer immunotherapy provide potential for developing effective cancer vaccines, despite current challenges. Researchers can overcome barriers to cancer vaccine use by identifying particular targets and establishing stronger immune responses [8]. Despite numerous attempts to develop cancer vaccinations, this remains true. Despite the fact that the human papillomavirus (HPV) is responsible for 70% of cervical malignancies and the hepatitis B virus can cause liver cancer, the Food and Drug Administration in the United States has just recently approved two preventative vaccines. The U.S. FDA has approved PROVENGE (sipuleucel-T), the first therapeutic cancer vaccination for hormone-resistant prostate cancer [9]. Clinical trials are exploring the use of customized cancer vaccines in concert with checkpoint blockade modulators or cytokine treatments to treat various solid and metastatic tumors, with promising findings [10, 11]. Cancer vaccines are categorized into four types: those based on tumor cells or immune cells; those based on peptides; There are two types of vectors: viral and nucleic acid-based [12]. Vaccines made from nucleic acids (DNA or RNA) hold significant potential for various reasons. Nucleic acid vaccines provide the benefit of delivering many antigens at once, covering a greater spectrum of TAAs or somatic tumor changes. This increases the likelihood of overcoming vaccine resistance by generating a humoral and cell-mediated immune response [13]. Nucleic acid vaccines offer the added benefit of covering a wider range of TAAs or somatic tumor changes . Secondly, nucleic acid vaccines are less limited by human HLA types, resulting in bigger T cell responses. Full-length tumor antigens can be encoded, allowing APCs to present or cross-present several epitopes with patient-specific HLA class I and II. Nucleic acid vaccines encode full-length tumor antigens, allowing APCs to display several epitopes [8].

Nucleic acid vaccines, including mRNA and DNA, can encode several tumor antigens . Nucleic acid vaccines can create multiple antigens at once, unlike traditional protein-based vaccinations that only target certain ones. This character this characteristic enhances the immune response to many tumor-associated antigens [14]. In preclinical investigations, researchers have produced mRNA vaccines that encode several tumor antigens, including neoantigens unique to each patient, leading to improved anticancer immune responses [15].HLA molecules are crucial for delivering antigens to the immune system [16]. However, the genetic variety of HLA types across India vaccination development can be challenging due to individual differences, as a vaccination targeting one HLA type may not be successful for others [17]. Nucleic acid vaccines have advantages in this area. Nucleic acid vaccines, which encode the antigen directly in mRNA or DNA, eliminate the need for HLA matching. The recipient's cells digest the generated antigen, presenting peptides on their surface regardless of HLA type [18]. Several investigations have shown that a wide immune response can be generated regardless of HLA type [10]. For example, in a clinical trial. Personalized neoantigens in an mRNA-based cancer vaccine were found to stimulate immune responses across many HLA types, indicating potential for widespread use [19]. Nucleic acid vaccines are safe for both preventive and therapeutic usage, as they do not transmit illnesses and are produced without any harmful ingredients. Protein or viral contaminations [20]. In recent years, mRNA vaccines have emerged as a potentially useful alternative to DNA vaccines for preventing infectious disorders and treating cancer. Compared to DNA, mRNA has several advantages as a cancer vaccine, including: Antigens can be translated from mRNA in a single step in both dividing and non-dividing cells after being taken up into the cytoplasm . Compared to DNA vaccines, mRNA vaccines often produce more protein [21]. mRNA vaccines are unable to incorporate into cells. The genomic sequence prevents insertional mutagenesis . In 1990, it was shown that direct injection of in vitro transcription (IVT) mRNA into mice skeletal muscle cells may efficiently create an mRNA vaccine (reference . Concerns about mRNA instability, poor in vivo transport, and high intrinsic innate immunogenicity may have hindered the initial attempt to analyze the synthesis of mRNA vaccinations . In recent decades, technological advancements have made mRNA vaccination a more viable option [22].

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:04/April-2024 Impact Factor- 7.868 www.irjmets.com

Modifying the mRNA backbone and untranslated sections can improve RNA stability, resistance to RNases, and translation-friendliness .Purifying techniques have improved access to mRNA products, eliminating double-stranded contaminations [23].

This reduces non-specific activation of the body's innate immune system . Incorporating messenger RNA (mRNA) with delivery vehicles such as lipid nanoparticles, polymers, and peptides has improved mRNA distribution in living organisms . mRNAs have broad use in IVT techniques . mRNA vaccines now provide significant advantages over traditional immunization methods because to advancements in production scale [24]. The benefits include lower production costs and potential for wider application. In terms of Cancer Previously, clinical trials focused on non-replicating mRNAs [25]. Self-amplifying mRNAs (SAM) are being studied for their potential application in treating cancer and infectious diseases .SAM are cost-effective in the long term and have a smaller impact per dose . Over 20 mRNA-based immunotherapies have entered clinical trials, with encouraging results for treating solid tumors [26]. Furthermore, mRNA vaccines offer a significant advantage over anti-cancer immunotherapies in terms of avoiding the Coronavirus infection has spread across the globe [27].

The FDA has approved two mRNA-based vaccines, one from Pfizer-BioNTech and one from Moderna, for COVID-19 emergency use. This has resulted in a significant increase in market value and interest in cancer and infectious disease applications [28]. The study suggests that using mRNA vaccines could help overcome hurdles in cancer immunotherapies. This review article addresses many aspects relevant to mRNA vaccines in cancer immunotherapy. It begins with: This article covers the basic pharmacology of mRNA vaccines and recent advancements in the technique. The article focuses on optimizing mRNA translation and stability, modulating immunogenicity, and progressing with mRNA vaccine administration. The article covers many delivery strategies, including as ex vivo loading of DCs, in vivo injection of naked mRNA, physical delivery methods, protamine, and cationic lipid and polymer-based administration. The review discusses the development of mRNA cancer vaccines, including both DC and direct injection methods. It also highlights. Topics covered include therapeutic concerns and obstacles, manufacturing practices, and regulatory implications of mRNA vaccines. This article examines strategies for improving mRNA translation efficiency and overcoming innate immunogenicity, such as modifying the five-prime cap, optimizing untranslated regions, optimizing open reading frames' codons, modifying poly(a) tails, modifying nucleosides, and purifying IVT-mRNA[29].The article explores the immunogenicity of mRNA and its paradoxical effects in cancer immunotherapy. It also examines self-amplifying mRNA vaccines. Structure, benefits, and deliveries. The review discusses the use of lipid nanoparticles (LNPs) to deliver mRNA cancer vaccines, including their effectiveness and immunogenicity. It also discusses mechanistic studies, functional modifications of LNPs, formulation and manufacturing of LNP mRNA vaccines, polymer-based and peptide-based delivery systems, and other formulations. The article covers the injection techniques and clinical applications of mRNA cancer vaccines. Finally, the review addresses the article covers immunostimulants, tumor-associated antigens, neoantigens, tailored vaccinations, and future perspectives on RNA-based cancer immunotherapy[30].

II. CANCER IMMUNOTHERAPIES

Cancer immunotherapy uses the immune system to target and eliminate cancer cells, making it a groundbreaking treatment option . The immune system detects and eliminates aberrant cells in the body, including cancer cells Cancer cells use several mechanisms to avoid the immune system and grow unchecked . Immunotherapy boosts the immune system's ability to recognize and eliminate cancer cells [31].

Immune-checkpoint inhibitors

Immune checkpoint inhibitors are cancer immunotherapy that targets immune cells' checkpoints. These checkpoints operate as Regulators or "brakes" on the immune system inhibit excessive immune responses that can cause autoimmunity [32]. One well-known checkpoint molecule is programmed cell death protein 1 (PD1). T cells, which recognize and eliminate cancer cells, express the protein on their surface [18]. CTLA-4, a checkpoint molecule, is largely present on the surface of Regulatory T cells [33]. Cancer cells commonly use checkpoint molecules to avoid immune identification and attack. They can express ligands (e.g., PD-L1) that bind to immune cell checkpoints and inhibit immunological responses. This prevents cancer cells from being eliminated by the immune system [34]. Immune checkpoint inhibitors interrupt inhibitory signals, allowing the

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:04/April-2024 Impact Factor- 7.868 www.irjmets.com

immune system to recognize and kill cancer cells. These inhibitors bind to PD-1 or CTLA-4 and block cancer cells' ligands from engaging with the checkpoint molecules . This boosts the immune system, allowing T cells to identify and eradicate cancer cells more efficiently. Checkpoint inhibitors improve anti-tumor immunity by reducing the immune system's "brakes". Immune cells can more efficiently infiltrate tumors, detect cancer-specific antigens, and mount a strong immune response against them. This can lead to tumor shrinking and better results for cancer patients. It's vital to note the checkpoint. Inhibitors are used to treat cancers such as melanoma, lung, kidney, bladder, and others. Some patients have shown great success, with long-lasting responses and better survival rates. However, their efficiency varies according on cancer kind and patient characteristics [35].

Tumor-infiltrating lymphocyte (TIL) therapy

Tumor-infiltrating lymphocyte (TIL) therapy uses a patient's immune system to fight cancer cells. TIL treatment involves isolating immune cells (lymphocytes) from the patient's tumor sample. In the laboratory, lymphocytes that have entered the tumor are enlarged and activated [36]. After generating a sufficient number of TILs, they are infused back into the patient [30]. TIL treatment aims to boost the immune system's anti-tumor response by increasing the number of activated T cells capable of targeting cancer cells. The therapy reintroduces modified TILs to boost the immune response against tumors [37].

TIL treatment can alter the tumor microenvironment by enhancing immune cell infiltration. This creates a hostile environment for cancer cells and improves the anti-tumor immune response .TIL therapy is a promising treatment for cancer that uses the patient's immune system to target and eradicate cancer cells . Upon infusion, enlarged TILs move to the tumor site and interact with cancer cells through recognition.

The expression of tumor-specific antigens. The contact stimulates TILs, causing the release of cytotoxic chemicals and immune-stimulating cytokines. TILs use cytotoxic chemicals like perforin and granzymes to target and kill cancer cells . Secreted cytokines recruit and activate other immune cells, increasing the anti-tumor response.

TIL treatment not only eliminates cancer cells but also modifies the tumor microenvironment [38]. Tumors can suppress immune cells, allowing cancer cells to elude detection.

Activated TILs can disrupt immune suppression by infiltrating the tumor and changing the balance of immune cell types [32]. This alteration in the tumor microenvironment can enhance anti-tumor immune responses. TIL therapy is currently being researched and its effectiveness varies based on factors such as cancer kind and stage, TIL quality and quantity, and patient immune condition.

Ongoing investigations aim to optimize TIL expansion strategies, select tumor-specific TILs, and explore combination therapy.

Increase the effectiveness of TIL-based therapy. TIL therapy is being studied both as a standalone therapy and in combination with other cancer treatments [39]. Researchers are exploring the combination of TIL treatment and immune checkpoint inhibitors to boost the anti-tumor immune response. Immune checkpoint drugs can unblock the immune system, allowing TILs to effectively attack cancer cells . Additionally, continuous attempts are being made to address some of the problems associated with TIL therapy . One difficulty is the restricted availability of TILs from certain tumor types or patients with poor TIL infiltration. Researchers are investigating techniques to create TILs can be expanded from tiny tumor samples or improved using genetic engineering techniques [40]. Personalized TIL therapy involves tailoring TILs to target unique antigens in a patient's tumor. This strategy entails identifying and creating TILs that can detect and target specific antigens expressed by the patient's tumor. Personalized TIL therapy has showed promising results in early clinical trials, potentially improving therapeutic efficacy by targeting tumor-specific antibodies.

TIL therapy has the potential to revolutionize cancer treatment [41]. By harnessing the power.

TIL treatment targets the immune system to battle cancer, potentially improving patient outcomes and quality of life. Future clinical research will shed light on the most effective application of TIL therapy for cancer treatment [42].

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:04/April-2024 Impact Factor- 7.868 www.irjmets.com

CAR-T cell therapy

CAR-T cell therapy is a novel cancer treatment that modifies a patient's T cells to improve their ability to recognize and treat cancer cells. attack the cancer cells . The method begins with collecting the patient's T cells from their blood. T cells are genetically modified to display a CAR on their surface. The CAR recognizes a specific antigen on cancer cells .

CAR-T cells are created in the lab and then put into the patient's body. Modified CAR-T cells can target and bind to cancer cells that express the targeted antigen, leading to a strong immune response against the tumor. This medication has shown effective in treating various blood malignancies, including leukemia and lymphoma. The target antigen is highly expressed [43].

CAR-T cell therapy is a tailored and highly targeted technique that uses the patient's immune system to combat cancer. Once injected.

CAR-T cells can grow and stay in the body, resulting in a long-lasting anti-tumor response . CAR-T cells can detect and kill cancer cells throughout the body, including in hard-to-reach places. CAR-T cell therapy is especially helpful for malignancies that have spread or are resistant to previous treatments. CAR-T cell treatment has the benefit of being very specific . The CAR targets a specific antigen on cancer cells while limiting harm to healthy cells. This tailored strategy decreases the possibility of being off target.

Traditional cancer therapies, such as chemotherapy and radiation, sometimes result in adverse effects [44]. Although successful, CAR-T cell therapy may have negative effects. Excessive immunological reaction, or cytokine release syndrome (CRS), can occur when the immune system is activated. CRS symptoms include flu-like symptoms, fever, low blood pressure, and in severe cases, organ damage.

Neurotoxicity is a possible adverse effect that can cause neurological symptoms such as disorientation and seizures [45]. Medical personnel regularly monitor individuals undergoing CAR-T cell therapy to manage any negative effects. CAR-T cell therapy has transformed cancer treatment, especially for specific types of blood malignancies . It has showed extraordinary efficacy. Some people have achieved long-term remissions and even cures. CAR-T cell treatment is being tested in clinical trials for various cancer types, with the goal of extending its benefits to a larger patient population . CAR-T cell treatment has demonstrated encouraging benefits in pediatric patients with relapsed or refractory malignancies [46]. CAR-T cell therapy has resulted in large remissions for children with acute lymphoblastic leukemia who did not respond to traditional treatments. This innovative medicine has opened up new treatment alternatives for young children who previously had few options . CAR-T cell therapy is constantly changing and improving. Researchers are looking on ways to improve its effectiveness and minimize side effects. One area of concentration is the Researchers are developing "second-generation" and "third-generation" CARs with additional signaling domains to improve CAR-T cell activation and persistence [47].

These improvements aim to enhance the anti-tumor response and expand the application of CAR-T cell therapy to additional forms of cancer. Solid tumors are more challenging to treat with CAR-T cell therapy than blood malignancies. Efforts are being made to overcome these limitations. CAR-T cell therapy can be combined with other treatments, such as immune checkpoint inhibitors or targeting numerous antigens. tried to enhance outcomes in solid tumors [48].

III. RECENT DEVELOPMENTS IN MRNA VACCINE TECHNOLOGY

Recently, several mRNA vaccine platforms have been developed and tested for immunogenicity and efficacy. Through the Genetic engineering enables more efficient translation of generated mRNA [54]. Table 1 summarizes the many types and categories of mRNA cancer vaccines. Various mRNA cancer vaccines are being developed, each with its own mechanism of action and benefits and drawbacks.

These cancer vaccines include ex vivo loading of patient-derived DCs and direct infusion of mRNA into tumors or surrounding tissue [49]. Some mRNA cancer vaccines target specific tumor antigens or neoantigens, while others use self-amplifying RNA vectors or lipid nanoparticles. Particles for better delivery. Strategies for enhancing the immune response to cancer cells include combining mRNA with adjuvants, immune checkpoint inhibitors, gene editing tools, or innovative delivery vehicles . Despite several methodologies, mRNA cancer vaccines encounter obstacles such as stability, immunogenicity, and manufacturing complexity. Although

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:04/April-2024 Impact Factor- 7.868 www.irjmets.com

numerous vaccines have showed promise in preclinical investigations, their efficacy in early clinical trials is limited. However, these inventive More research is needed to fully realize the potential of treatments for cancer. The introduction of non-toxic RNA carriers has extended the expression of antigens in vivo under specific conditions [50].

Certain vaccine formulas use novel adjuvants, while others generate strong immune responses even without established adjuvants . The section summarizes important breakthroughs in mRNA engineering and its implications for vaccine effectiveness. The development of mRNA-based treatments is separated into three phases, highlighting significant breakthroughs and advancements. The development of mRNA-based treatments is separated into three phases, highlighting significant breakthroughs and advancements[51].

Enhancement of mRNA translation stabilit

The 5′ and 3′ UTRs that surround the coding region have a substantial impact on the stability and translation of mRNA, both of which are important challenges for vaccine development.

operation . It has been demonstrated that regulation sequences, which can be derived from Eukaryotic or viral genes, can increase the half-life and synthesis of therapeutic mRNAs . Effective protein synthesis from mRNA requires a 5′ cap structure . In order to successfully synthesize protein from mRNA, a 5′ cap structure is needed . 5′ caps can be added during or after transcription, depending on the use case, employing an anti-reverse cap analogue, synthetic cap, or vaccinia virus capping enzyme [52]. A sufficient length of poly(A) must be added to mRNA to guarantee that it is translated and stable, either straight from the utilizing poly(A) polymerase or by encoding DNA template . Protein translation is also impacted by the codons used . To promote protein synthesis from mRNA, it is customary to substitute common synonymous codons with plentiful cognate tRNA in the cytosol, albeit this paradigm has been questioned . It has been demonstrated that increasing the G:C composition of sequences increases both protein expression in vivo and steady-state mRNA levels in vitro . Although altering the makeup of codons or nucleosides can positively regulate protein production, it is also feasible to negatively affect the expression of cryptic T cell epitopes found in alternative reading frames, translation kinetics and accuracy, mRNA secondary structure, and concomitant protein folding kinetics and accuracy30.

The immune response's intensity and specificity may be influenced by each of these variables [53].

IV. THERAPEUTIC ISSUES AND DIFFICULTIES

Good manufacturing practice production

NTPs, recombinant enzymes, and a DNA template are used in the in vitro synthesis of messenger RNA . Compact GMP facilities can produce mRNA because of its high reaction yield and ease of use [268]. Nucleotide and cap ping chemistry, length of RNA, and product purification control the sequence-independent production process [269].

On the other hand, excessive length could cause issues [54].

This method can produce any encoded protein immunogen, making it ideal for quickly responding to emerging infectious illnesses . The synthetic versions of all the enzymes and reaction elements required for GMP mRNA production are obtainable from commercial suppliers. chemicals or reagents without animal components that are made by bacteria . Phage polymerases, capping enzymes, NTPs, and traceable plasmid DNA of GMP quality are all accessible . Some ingredients cost a lot of money or are hard to find . More reasonably priced GMP source materials could become available when mRNA treatment output rises . The same multistep process used for research-scale synthesis, plus additional testing to ensure safety and potency, is employed for GMP mRNA production, which starts with DNA template synthesis and ends with enzymatic IVT [55]. Depending on the chemistry and mRNA construct, this method can require minor adjustments to change the nucleosides, cap tech, niques, or taking a template out . Runoff transcripts with a 3′-terminal poly(A) tract are created by using a restriction enzyme to linearize the DNA of the Escherichia coli template plasmid [56]. Using NTPs (like T7, SP6, or T3), a bacteriophage-derived DNA-dependent RNA polymerase generates mRNA [57]. DNA template is destroyed by DNase [58]. mRNA is chemically or enzymatically bound to facilitate in vivo translation [59]. Under optimal circumstances, mRNA synthesis can produce 2 g l1 of full-length mRNA. Following synthesis, mRNA is purified in order to eliminate any leftover nucleotides, enzymes, DNA, or RNA . It is more feasible to

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:04/April-2024 Impact Factor- 7.868 www.irjmets.com

use derivatized microbeads in batch or column forms for large-scale purification in clinical settings [60]. To avoid interferon-dependent translation suppression, dsRNA needs to be extracted from different mRNA platforms [61]. The lab oratory-scale success of reverse-phase FPLC has been achieved, and scalable aqueous purification methods are currently under investigation. Vials can be filled for clinical use once mRNA has been sterile-filtered and preserved in a final buffer. Both chemical and enzymatic breakdown of RNA are possible. Antioxidants and chelators may be present in formulation buffers to stop mRNA instability [62]. creating drugs using messenger RNA. Immunizations are typically kept at 70 °C, however warmer formulations are being tested by researchers. One can create stable formulations that can be refrigerated or kept at room temperature. The RNActive platform can be lyophilized and kept for three years at 5–25 °C and for six months at 40 °C. Freeze-dried naked mRNA keeps for at least ten months in the fridge, according to a different study . RNase inhibitors or mRNA packaged in nanoparticles can increase product stability [63]. For lipid-encapsulated mRNA, at least six months of stability have been shown (Arbutus Biopharma, personal communication); however, longer-term unfrozen preservation has not been recorded [64].

Regulatory aspects

As of right now, no firm regulations pertaining to mRNA vaccination products have been created by the FDA or the European Medicines Agency (EMA) . As possible the EMA and the FDA are in charge of an increasing number of clinical trials, which indicates that these regulatory bodies have approved the techniques put forth by different organizations to show that their products are safe and appropriate for human testing [65]. Since that immunizations employ mRNA, a form of genetic immunogen, it is sense to anticipate that the guidelines that have been set for with relatively small modifications, DNA vaccines and gene therapy vectors will be able to be used on mRNA to take into account its unique characteristics [66]. In analyzing the EMA guidelines for RNA vaccines, some researchers point out how there are significant differences in the rules governing the therapeutic and pre-ventative uses of RNA vaccines [67]. There are similarities between the claims made in these guidance publications and the results of recently published clinical research, regardless of the exact classification under the current recommendations. Both sets of resources share these commonalities. The findings indicating biodistribution of an mRNA vaccine against the influenza virus were included in a recent publication ,and durability in mice, immunity, local reactogenicity, and toxicity in humans, as well as protection against disease in a pertinent animal model (ferrets). It is anticipated that specific guidelines outlining the prerequisites for creating and researching novel mRNA vaccines will be produced as mRNA products continue to attract increasing attention from the vaccination sector [68].

V. USES OF MRNA VACCINES IN BOTH THERAPEUTIC AND PREVENTATIVE SETTINGS

Those who are susceptible to exposure to a particular pathogen are given the mRNA vaccinations. gen, including bacteria or viruses. The mRNA vaccines teach the body's cells to create a safe fragment of the pathogen, usually an antigen or protein, which subsequently triggers an immunological reaction. The production of antibodies and the activation of immune cells that are specific to the pathogen are two aspects of this immune response.

When the person is later exposed to the infection, their immune system will be better able to identify it and fight it off. Releasing an illness or lessening its intensity. Numerous infectious disorders, including as COVID-19, influenza, and others, have been effectively treated with mRNA vaccines [69]. For those who have already contracted a particular condition, such as cancer or a particular virus, the mRNA vaccines are utilized as a therapy option. Therapeutic mRNA vaccines function by giving cells genetic instructions that encourage them to create particular proteins that are indicative of the disease . These proteins may be viral proteins in the case of a viral infection or tumor-specific antigens in the case of malignancy. By generating these dis the immune system is prompted by ease-specific proteins to identify and launch an immunological reaction against the virulent or sick cells [315]. Therapeutic mRNA vaccines have the potential to improve the body's capacity to identify and destroy cancer cells, which makes them promising for use in cancer treatment [70].

e-ISSN: 2582-5208
International Research Journal of Modernization in Engineering Technology and Science
(Peer-Reviewed, Open Access, Fully Refereed International Journal)
Volume:06/Issue:04/April-2024 Impact Factor- 7.868 www.irjmets.com

VI. MRNA VACCINES' TOLERABILITY AND SAFETY

It has been acknowledged that mRNA vaccinations are generally well-tolerated and risk-free . There exist a few causes behind this. First off, the chance of contracting the disease that mRNA vaccines are intended to prevent or treat is eliminated because they do not include live viruses or other pathogens . Rather, they are made up of a little segment of genetic material that codes for a particular protein. Second, mRNA vaccines are temporary, which means that the mRNA swiftly deteriorates and is eliminated from the body when the genetic material is absorbed by cells and the protein is generated [71]. There won't be any long-term genetic changes thanks to this transient nature. Furthermore, mRNA vaccines do not combine with the host genome, hence reducing any possible long-term hazards even further. In addition, before they are approved, comprehensive clinical trials and thorough safety assessments are carried out to make sure they adhere to stringent safety requirements . As is common with most immunizations, adverse responses to mRNA vaccinations are usually minor and transient and include injection site soreness, tiredness, and fever . Moreover, a strong basis for the safety and tolerability of mRNA vaccines has been established by years of rigorous research and development of the underlying technology [72]. The mRNA in vaccines is meticulously designed and refined to increase stability and minimize any possible adverse consequences. Lipid nanoparticle delivery technologies, which shield mRNA and promote effective cellular absorption, are another advantage of modern mRNA vaccines . The strict regulatory procedures and extensive testing that mRNA vaccines go through before licensing are another important aspect ensuring their safety . In-depth preclinical research is conducted on these vaccinations in animals to assess their safety and effectiveness. Afterward, they proceed through several stages of clinical trials when thousands of people take part and their safety, immunogenicity, and effectiveness are carefully evaluated [73]. Furthermore, the comprehensive post-approval monitoring and surveillance systems provide the prompt identification and examination of any possible unfavorable incidents. By doing this continuous monitoring, it is made possible to rapidly address any uncommon or unexpected adverse effects and continuously analyze the safety profile of mRNA vaccines . Clinical trial results taken together with real-world data and the millions of people who have successfully received mRNA vaccinations demonstrates their exceptional tolerability and safety . The small hazards associated with mRNA vaccinations are greatly outweighed by their ability to prevent major infections, hospitalizations, and fatalities.

Ongoing research and observational studies also enhance our comprehension of these immunizations and guarantee their continued safety [74].

VII. CONCLUSION

In conclusion, the review paper highlights the significant advancements in cancer immunotherapy, particularly focusing on mRNA vaccines. Over the years, cancer immunotherapies have evolved significantly, with FDA approvals of checkpoint blockade modulators and CAR-T cell therapies demonstrating their efficacy and potential as successful treatment options. These immunotherapies have shown promising results in boosting the immune system's ability to recognize and eliminate cancer cells, thereby providing a viable alternative to standard cancer treatments. The paper emphasizes the role of cancer vaccines, especially mRNA vaccines, as a potential alternative for cancer prevention and treatment. Unlike traditional vaccines for infectious diseases, cancer vaccines target cancer cells by stimulating the immune system. This focused approach holds promise for transforming cancer treatment by offering tailored therapies with fewer adverse effects.

The review also discusses the challenges and ongoing research in cancer vaccine development, particularly focusing on nucleic acid-based vaccines like mRNA vaccines. Despite challenges such as the diverse nature of tumor antigens and immunological responses, advancements in mRNA vaccine technology have made them a more viable option. Modifications in mRNA stability, delivery systems, and manufacturing processes have improved the effectiveness and safety of mRNA vaccines. Furthermore, the paper highlights the recent developments in mRNA vaccine technology, including enhancements in mRNA translation stability, manufacturing practices, and regulatory considerations. The potential uses of mRNA vaccines in both therapeutic and preventive settings are discussed, emphasizing their tolerability and safety profiles. Overall, the review paper underscores the significant progress in cancer immunotherapy, particularly in the context of mRNA vaccines, and emphasizes the potential of these vaccines to revolutionize cancer treatment by providing targeted, effective, and well-tolerated therapies.

ACKNOWLEDGEMENTS

Authors (Vikin P. Nagrik) are greatful to, Abhishek S. Jaware, Naval D. Chaudhari ,Tushar D. Gudade ,Pranjal P.Mhaske , Satish S. Palkar , Tanvi V. Bhave , Rutuja R. Hajare , Sant Gadage baba Amravti University , Gawande Collage Of Pharmacy, Sakharkherda.

VIII. REFERENCES

[1] Lu YC, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol. 2016;28(1):22–7.
[2] Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):1–23.
[3] Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52(1):17–35.
[4] Li W, Deng Y, Chu Q, Zhang P. Gut microbiome and cancer immuno therapy. Cancer Lett. 2019;447:41–
[5] Dobosz P, Dzieciątkowski T. The Intriguing History of Cancer Immuno therapy. Front Immunol. 2019;2965.
[6] Liu S, Galat V, Galat4 Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14:1–7.
[7] Tan S, Li D, Zhu X. Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother. 2020;124:109821.
[8] Xu Z, Wang X, Zeng S, Ren X, Yan Y, Gong Z. Applying artifi cial intelligence for cancer immunotherapy. Acta Pharm Sin B. 2021;11(11):3393–405.
[9] Stasiak M, Zawadzka-starczewska K, Lewiński A. Significance of HLA Haplotypes in Two Patients with Subacute Thyroiditis Triggered by mRNA-Based COVID-19 Vaccine. Vaccines. 2022;10(2):280.
[10] Quatrini L, Mariotti FR, Munari E, Tumino N, Vacca P, Moretta L. The immune checkpoint PD-1 in natural killer cells: Expression, function and targeting in tumour immunotherapy. Cancers (Basel). 2020;12(11):3285.
[11] Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, et al. mRNA therapeutics in cancer immunotherapy. Mol Cancer. 2021;20(1):1–24.
[12] Zhao X, Pan X, Wang Y, Zhang Y. Targeting neoantigens for cancer immunotherapy. Biomark Res. 2021;28(7):365–70.
[13] Bergman PJ. Cancer Immunotherapies. Vet Clin North Am - Small Anim Pract. 2019;49(5):881–902.223. Yoshikawa T. Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers. Vaccine. 2021;39(41):6174-81.
[14] Piccaluga PP, Di Guardo A, Lagni A, Lotti V, Diani E, Navari M, et al. COVID-19 Vaccine: Between Myth and Truth. Vaccines. 2022;10(3):349.
[15] Zabaleta N, Dai W, Bhatt U, Hérate C, Maisonnasse P, Chichester JA, et al. An AAV-based, room-temperature-stable, single-dose COVID-19 vac cine provides durable immunogenicity and protection in non-human primates. Cell Host Microbe. 2021;29:1437-1453.e8.
[16] Manara C, Brazzoli M, Piccioli D, Taccone M, D'Oro U, Maione D, et al. Co-administration of GM-CSF expressing RNA is a powerful tool to enhance potency of SAM-based vaccines. Vaccine. 2019;37:4204–13.
[17] Abbasi S, Uchida S. Multifunctional immunoadjuvants for use in mini malist nucleic acid vaccines. Pharmaceutics. 2021;13(5):644.
[18] Broderick KE, Humeau LM. Enhanced delivery of dna or rna vaccines by electroporation. Methods Mol Biol. 2017:193-200.
[19] Lopes A, Bastiancich C, Bausart M, Ligot S, Lambricht L, Vanvarenberg K, et al. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models. J Immunother Cancer. 2021;9(4).
[20] Starostina E V., Sharabrin S V., Antropov DN, Stepanov GA, Shevelev GY, Lemza AE, et al. Construction and immunogenicity of modified mrna-vaccine variants encoding influenza virus antigens. Vaccines. 2021;9(5):452.
[21] Papukashvili D, Rcheulishvili N, Liu C, Wang X, He Y, Wang PG. Strategy of developing nucleic acid-based universal monkeypox vaccine candi dates. Front. Immunol. 2022;13.
[22] Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of Lipid Nanoparticles for RNA Delivery. Acc Chem Res.

2022;55:2–12.

[23] Haroun F, Alharbi M, Hong A. Case series on the safety of mRNA COVID19 vaccines in cancer patients undergoing treatment. J Clin Oncol. 2021;39:e14562.

[24] Sharbi-Yunger A, Grees M, Cafri G, Bassan D, Eichmüller SB, Tzehoval E, et al. A universal anti-cancer vaccine: Chimeric invariant chain.

[25] Bandola-Simon JM, Roche PA. Dendritic cells dysfunction in tumor draining lymph nodes. J Immunol. 2019;202:135.16.

[26] Moreira A, Erdmann M, Uslu U, Vass V, Schuler G, Schuler-Thurner B. Blood eosinophilia is an on-treatment biomarker in patients with solid tumors undergoing dendritic cell vaccination with autologous tumor RNA. Pharmaceutics. 2020;12(3):210.

[27] Morrissey ME, Byrne R, Nulty C, McCabe NH, Lynam-Lennon N, Butler CT, et al. The tumour microenvironment of the upper and lower gastro intestinal tract differentially influences dendritic cell maturation. BMC Cancer. 2020;20(1):1-3.

[28] Song HY, Han JM, Byun EH, Kim WS, Seo HS, Byun EB. Bombyx batryti catus protein-rich extract induces maturation of dendritic cells and th1 polarization: A potential immunological adjuvant for cancer vaccine. Molecules. 2021;26(2):476.

[29] Arance Fernandez AM, Baurain J-F, Vulsteke C, Rutten A, Soria A, Carrasco J, et al. A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity. J Clin Oncol. 2019;37:2641.

[30] Li X, Zheng J, Chen S, Meng F dong, Ning J, Sun S lan. Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK/elF2α/ ATF4/CHOP pathway in breast cancer. Cell Death Dis. 2021;12(4):314.

[31] Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 2018;18(3):168-82.

[32] Liu S, Sirohi K, Verma M, McKay J, Michalec L, Sripada A, et al. Optimal identification of human conventional and nonconventional (CRTH2 IL7Rα–) ILC2s using additional surface markers. J Allergy Clin Immunol. 2020;146:390–405.

[33] Gumińska N, Zakryś B, Milanowski R. A New Type of Circular RNA derived from Nonconventional Introns in Nuclear Genes of Euglenids. J Mol Biol. 2021;433(3):166758.

[34] Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 2008;31:180–8.

[35] Hervent A-S, Vandekerckhove L, De Keulenaer GW. Neuregulin-1 antagonizes myocardial fibrosis and diastolic dysfunction in angioten sin-II treated mice. Eur Heart J. 2013;34:P2434.

[36] Khranovska N, Skachkova O, Ganul A, Gorbach O, Sovenko V, Svergun N, et al. Results from phase iii trial of dendritic cell based vaccine immuno therapy in patients with-iiia stage non-small-cell lung cancer. J Thorac Oncol. 2013;8:S910.

[37] Pepini T, Pulichino A-M, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, et al. Induction of an IFN-Mediated Antiviral Response by a Self Amplifying RNA Vaccine: Implications for Vaccine Design. J Immunol. 2017;198:4012–24.

[38] Rotterdam J, Thiaucourt M, Schwaab J, Reiter A, Kreil S, Steiner L, et al. Antibody Response to Vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms. Blood. 2021;138:218.

[39] Bai X, Wong CC, Pan Y, Chen H, Liu W, Zhai J, et al. Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells. J Immunother Cancer. 2022;10(2).

[40] Lee M, Shim SY. Inhibitory effects of eriodictyol-7-O-β-d-glucuronide and 5,7-dihydroxy-4-chromene isolated from chrysanthemum zawad skii var. latilobum in FcεRI-mediated human basophilic KU812F cell activation. Molecules. 2020;25(4):994.

[41] Mulder FJ, Klufah F, Janssen FME, Farshadpour F, Willems SM, de Bree R, et al. Presence of Human Papillomavirus and Epstein–Barr Virus, but Absence of Merkel Cell Polyomavirus, in Head and Neck Cancer of Non Smokers and Non-Drinkers. Front Oncol. 2021;10:560434.

[42] Ogasawara S, Kanzaki H, Koroki K, Kanayama K, Maruta S, Kobayashi K, et al. Phase I study of a new concept cancer vaccine composed artificial intel ligence (AI)-designed shared-antigen peptides plus combined synergisti cally activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCE. J Clin Oncol. 2020;38:TPS595.

[43] Song X, Jiang Y, Zhang W, Elfawal G, Wang K, Jiang D, et al. Transcuta neous tumor vaccination combined with anti-programmed death-1 monoclonal antibody treatment produces a synergistic antitumor effect. Acta Biomater. 2022;140:247–60.

[44] Fehervari Z. Intranasal vaccination. Nat Immunol. 2021;22:1071.

[45] Harda K, Szabo Z, Juhasz E, Dezso B, Kiss C, Schally A V., et al. Expres sion of somatostatin receptor subtypes (SSTR-1–SSTR-5) in pediatric hematological and oncological disorders. Molecules. 2020;25(23):5775.

[46] Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, et al. Beyond conventional immune-checkpoint inhibition — novel immu notherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;199–214.

[47] Liu S, Feng Y, Huang Y, Jiang X, Tang C, Tang F, et al. A GM1 gangliosi dosis mutant mouse model exhibits activated microglia and disturbed autophagy. Exp Biol Med. 2021;246:1330–41.

[48] Chen D, Li X, Li H, Wang K, Tian X. Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carci noma. J Oncol. 2022;2022.

[49] Miloradovic D, Miloradovic D, Markovic BS, Acovic A, Harrell CR, Djonov V, et al. The Effects of Mesenchymal Stem Cells on Antimelanoma Immunity Depend on the Timing of Their Administration. Stem Cells Int. 2020;2020.

[50] Miyashita Y, Yoshida T, Takagi Y, Tsukamoto H, Takashima K, Kouwaki T, et al. Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination. NPJ Vaccines. 2022;7(1):16.

[51] Lee MJ, Lee I, Wang K. Recent Advances in RNA Therapy and Its Car riers to Treat the Single-Gene Neurological Disorders. Biomedicines. 2022;10(1):158.

[52] Lou G, Anderluzzi G, Schmidt ST, Woods S, Gallorini S, Brazzoli M, et al. Delivery of self-amplifying mRNA vaccines by cationic lipid nano particles: The impact of cationic lipid selection. J Control Release.

[53] Improving the Specificity of RNAi-Based Therapeutics for Hunting ton's Disease. Mol Ther. 2011;19:S320.

[54] Dewi KS, Kusharyoto W. Strategy for Designing the Synthetic Gene Encoding Human papillomavirus Major Capsid L1 Protein for Heterolo gous Expression in Escherichia coli System. Biog J Ilm Biol. 2020;8:225.

[55] Tudek A, Krawczyk PS, Mroczek S, Tomecki R, Turtola M, Matylla-Kulińska K, et al. Global view on the metabolism of RNA poly(A) tails in yeast Saccharomyces cerevisiae. Nat Commun. 2021;12(1):4951.

[56] Zhou S, Hill C, Sarkar S, Tse V, Sheahan T, Baric R, et al. RNHC inhibits SARS-CoV-2 in vitro but is mutagenic in mammalian cells. Top Antivir Med. 2021;29:135–6.

[57] Baiersdörfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U, et al. A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. Mol Ther - Nucleic Acids. 2019;15:26–35.

[58] Dilley KA, Voorhies AA, Luthra P, Puri V, Stockwell TB, Lorenzi H, et al. The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing. PLoS One. 2017;12.

[59] Javaheri B, Stern A, Lara N, Dallas M, Zhao H, Liu YY-BY, et al. Rubio D: Spontaneous human adult stem cell transformation. Cancer Res. 2005;65(8):3035–9 J Bone Miner Res. 2011;7:1–9.

[60] Gehring NH, Roignant JY. Anything but Ordinary – Emerging Splic ing Mechanisms in Eukaryotic Gene Regulation. Trends Genet. 2021;37(4):355-72.

[61] Kanagasabai R, Serdar L, Karmahapatra S, Kientz CA, Ellis J, Ritke MK, et al. Alternative RNA processing of topoisomerase IIα in etoposide-resistant human leukemia K562 cells: Intron retention results in a novel C-terminal truncated 90-kDa isoform. J Pharmacol Exp Ther. 2017;360:152–63.

[62] Wei L, Zhang Q, Zhong C, Aubé J, Welch DR, Wu X, et al. Abstract P4–01–16: Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR. Cancer Res. 2022;82:P4-1-

16-P4-01–16.

[63] Su D, Chan CTY, Gu C, Lim KS, Chionh YH, McBee ME, et al. Quantita tive analysis of ribonucleoside modifications in tRNA by HPLC-coupled mass spectrometry. Nat Protoc. 2014;9:828–41.

[64] Giri P, Kumar G. Molecular Aspects of Small Molecules-Poly(A) Interac tion: An Approach to RNA Based Drug Design. Curr Med Chem. 2009;16:965–87.

[65] Moudgil A, Wilkinson MN, Chen X, He J, Cammack AJ, Vasek MJ, et al. Self-Reporting Transposons Enable Simultaneous Readout of Gene Expression and Transcription Factor Binding in Single Cells. Cell. 2020;182:992-1008.e21.

[66] Anderluzzi G, Lou G, Woods S, Schmidt ST, Gallorini S, Brazzoli M, et al. The role of nanoparticle format and route of administra tion on self-amplifying mRNA vaccine potency. J Control Release. 2022;342:388–99.

[67] Tsiambas E, Chrysovergis A, Papanikolaou V, Mastronikolis N, Ragos V, Batistatou A, et al. Impact of Ribosome Activity on SARS-CoV-2 LNP – Based mRNA Vaccines. Front Mol Biosci. 2021;8:654866.

[68] Beaudoin JD, Perreault JP. 5′-UTR G-quadruplex structures acting as translational repressors. Nucleic Acids Res. 2010;38:7022–36.

[69] Jungers CF, Djuranovic S. Modulation of miRISC-Mediated Gene Silenc ing in Eukaryotes. Front Mol Biosci. 2022;9:832916.

[70] Tomé I, Francisco V, Fernandes H, Ferreira L. High-throughput screening of nanoparticles in drug delivery. APL Bioeng. 2021;5(3):031511.

[71] Byszewska M, Śmietański M, Purta E, Bujnicki JM. RNA methyltrans ferases involved in 5′ cap biosynthesis. RNA Biol. 2014;11(12):1597-607.

[72] Lauridsen LH, Doessing HB, Long KS, Nielsen AT. A capture-SELEX strat egy for multiplexed selection of RNA aptamers against small molecules. Methods Mol Biol. 2018;291–306.

[73] Papies J, Emanuel J, Heinemann N, Kulić Ž, Schroeder S, Tenner B, et al. Corrigendum: Antiviral and Immunomodulatory Effects of Pelargonium sidoides DC. Root Extract EPs® 7630 in SARS-CoV-2-Infected Human Lung Cells. Front Pharmacol. 2021;12:2871.

[74] Takahashi-Nakaguchi A, Shishido E, Yahara M, Urayama SI, Ninomiya A, Chiba Y, et al. Phenotypic and Molecular Biological Analysis of Polymycovirus AfuPmV-1M From Aspergillus fumigatus: Reduced Fungal Virulence in a Mouse Infection Model. Front Microbiol. 2020;11:607795.